Il-17 receptor a antigen binding proteins
AssigneeAmgen Inc.
InventorsJoel TOCKER, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
Life of this patent
Estimating the term…
Loading patent…
AssigneeAmgen Inc.
InventorsJoel TOCKER, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
Estimating the term…
The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
An isolated antibody, comprising a human monoclonal antibody or IL-17 Receptor A binding fragment thereof that specifically binds IL-17 Receptor A and inhibits IL-17A from binding and activating said receptor.
An isolated monoclonal antibody, or IL-17 Receptor A-binding fragment thereof, comprising an isolated monoclonal antibody that binds to human IL-17 Receptor A and that competes for binding with an antibody selected from the group consisting of:
A method of treating a disease state associated with IL-17 Receptor A activation in a patient in need thereof, comprising administering to said patient a composition comprising an antibody that specifically binds IL-17 Receptor A and inhibits the binding of IL-17A, wherein said antibody is selected from the group consisting of:
Dependencies are inferred from the claim text.